Your browser doesn't support javascript.
loading
Broad evidence of xylazine in the UK illicit drug market beyond heroin supplies: Triangulating from toxicology, drug-testing and law enforcement.
Copeland, Caroline S; Rice, Kathleen; Rock, Kirsten L; Hudson, Simon; Streete, Peter; Lawson, Alexander J; Couchman, Lewis; Holland, Adam; Morley, Stephen.
Afiliación
  • Copeland CS; Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King's College London, London, UK.
  • Rice K; National Programme on Substance Abuse Deaths, London, UK.
  • Rock KL; Toxicology Unit, Leicester Royal Infirmary, Leicester, UK.
  • Hudson S; Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King's College London, London, UK.
  • Streete P; LGC Limited, Ely, UK.
  • Lawson AJ; Toxicology Department, Hampshire Scientific Services, Hampshire, UK.
  • Couchman L; Department of Toxicology, Birmingham Heartlands Hospital, Birmingham, UK.
  • Holland A; Analytical Services International Limited, St George's, University of London, London, UK.
  • Morley S; School of Psychological Sciences, University of Bristol, Bristol, UK.
Addiction ; 119(7): 1301-1309, 2024 07.
Article en En | MEDLINE | ID: mdl-38593992
ABSTRACT
BACKGROUND AND

AIMS:

Xylazine is a non-opioid sedative which has spread rapidly throughout the US illicit drug supply. This study aimed to describe the spread of xylazine throughout the UK illicit drug supply.

METHODS:

Xylazine detections in human biological samples were collated from toxicology laboratories operating in the United Kingdom with the date, location, case type, xylazine concentration and co-detected drugs (with quantifications where performed) detailed, where permitted, by the corresponding coroner. Drug-testing cases positive for xylazine were collated from the Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS) drug-testing postal service with the date, location, purchase intent and co-detected drugs detailed. Drug seizures made by UK law enforcement were communicated by the Office for Health Improvement and Disparities with the date and location detailed.

RESULTS:

By the end of August 2023, xylazine was detected in 35 cases from throughout toxicology, drug-testing and drug seizure sources covering England, Scotland and Wales. There were no cases reported from Northern Ireland. Xylazine was detected in biological samples from 16 people. In most cases where full toxicology results were provided, xylazine was detected with heroin and/or a strong opioid (n = nine of 11), but this polydrug use pattern was not evident in all cases (n = two of 11), suggesting a wider circulation of xylazine in the UK illicit drug market beyond heroin supplies. Evidence from WEDINOS supports this claim, as all 14 drug samples (100%) submitted from across the UK contained xylazine; however, in none of these cases was heroin the purchase intent but rather counterfeit prescription medication tablets (n = 11 of 14), tetrahydrocannabinol (THC) vapes (n = two of 14) or white powder (n = one of 14). Additional evidence for the spread of illicit xylazine comes from five drug seizures made by law enforcement.

CONCLUSIONS:

Xylazine has penetrated the UK illicit drug market and is not limited to heroin supplies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Xilazina / Drogas Ilícitas / Detección de Abuso de Sustancias / Heroína Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Addiction Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Xilazina / Drogas Ilícitas / Detección de Abuso de Sustancias / Heroína Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Addiction Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido